Author

Peter L Lakatos

ETROLIZUMAB VERSUS PLACEBO IN TUMOR NECROSIS FACTOR ANTAGONIST NAIVE PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED PHASE 3 LAUREL TRIAL
ETROLIZUMAB VERSUS PLACEBO IN TUMOR NECROSIS FACTOR ANTAGONIST NAIVE PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE RANDOMIZED PHASE 3 LAUREL TRIAL

Peter L Lakatos  et al.

ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB
ACHIEVEMENT OF STRINGENT EFFICACY ENDPOINTS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE TREATED WITH UPADACITINIB

Peter L Lakatos  et al.

IMPACT OF BIOLOGIC THERAPIES AND SMALL MOLECULES ON THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
IMPACT OF BIOLOGIC THERAPIES AND SMALL MOLECULES ON THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Peter L Lakatos  et al.

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 2: Surgical Management and Special Situations

Peter L Lakatos  et al.

HIGH DISEASE BURDEN OF CROHN'S DISEASE (CD) IN A LATIN AMERICAN IBD REFERENCE CENTER
HIGH DISEASE BURDEN OF CROHN'S DISEASE (CD) IN A LATIN AMERICAN IBD REFERENCE CENTER

Peter L Lakatos  et al.

THE RISK OF SYNCHRONOUS COLORECTAL CANCER IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND HIGH-GRADE DYSPLASIA
THE RISK OF SYNCHRONOUS COLORECTAL CANCER IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND HIGH-GRADE DYSPLASIA

Peter L Lakatos  et al.

DECLINING TRENDS OF REOPERATIONS AND DISEASE BEHAVIOR PROGRESSION BUT NOT FIRST RESECTIVE SURGERY IN CROHN’S DISEASE OVER DIFFERENT THERAPEUTIC ERAS – A PROSPECTIVE POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977–2020, DATA FROM THE VESZPREM COHO
DECLINING TRENDS OF REOPERATIONS AND DISEASE BEHAVIOR PROGRESSION BUT NOT FIRST RESECTIVE SURGERY IN CROHN’S DISEASE OVER DIFFERENT THERAPEUTIC ERAS – A PROSPECTIVE POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977–2020, DATA FROM THE VESZPREM COHO

Peter L Lakatos  et al.

BURDEN OF PERIANAL DISEASE AND PERIANAL SURGERY IN CROHN’S DISEASE OVER DIFFERENT THERAPEUTIC ERAS – A POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977–2020, DATA FROM THE VESZPREM COUNTY COHORT
BURDEN OF PERIANAL DISEASE AND PERIANAL SURGERY IN CROHN’S DISEASE OVER DIFFERENT THERAPEUTIC ERAS – A POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977–2020, DATA FROM THE VESZPREM COUNTY COHORT

Peter L Lakatos  et al.

RISK OF AND RISK FACTORS FOR COLORECTAL CANCER IN ULCERATIVE COLITIS – A POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977–2018, DATA FROM THE VESZPREM COUNTY COHORT
RISK OF AND RISK FACTORS FOR COLORECTAL CANCER IN ULCERATIVE COLITIS – A POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977–2018, DATA FROM THE VESZPREM COUNTY COHORT

Peter L Lakatos  et al.

LONG-TERM RESECTIVE AND PERIANAL SURGERY RATES IN CROHN’S DISEASE OVER DIFFERENT ERAS – A POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977–2020, DATA FROM THE VESZPREM COUNTY COHORT
LONG-TERM RESECTIVE AND PERIANAL SURGERY RATES IN CROHN’S DISEASE OVER DIFFERENT ERAS – A POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977–2020, DATA FROM THE VESZPREM COUNTY COHORT

Peter L Lakatos  et al.

LONG-TERM COLECTOMY RATES IN ULCERATIVE COLITIS OVER DIFFERENT ERAS – A POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977–2020, DATA FROM THE VESZPREM COUNTY COHORT
LONG-TERM COLECTOMY RATES IN ULCERATIVE COLITIS OVER DIFFERENT ERAS – A POPULATION-BASED STUDY FROM WESTERN HUNGARY BETWEEN 1977–2020, DATA FROM THE VESZPREM COUNTY COHORT

Peter L Lakatos  et al.

EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM SURGERY RATES IN IBD-U PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 1977–2018, DATA FROM THE VESZPREM COUNTY COHORT
EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM SURGERY RATES IN IBD-U PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 1977–2018, DATA FROM THE VESZPREM COUNTY COHORT

Peter L Lakatos  et al.

INCIDENCE, EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM SURGERY RATES IN IBD-U PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 1977–2020, DATA FROM THE VESZPREM COUNTY COHORT
INCIDENCE, EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM SURGERY RATES IN IBD-U PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 1977–2020, DATA FROM THE VESZPREM COUNTY COHORT

Peter L Lakatos  et al.

INCIDENCE, PREVALENCE, DISEASE PHENOTYPE AND MAXIMAL THERAPEUTIC STEP IN ULCERATIVE COLITIS PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 2007–2018, DATA FROM THE VESZPREM COUNTY COHORT
INCIDENCE, PREVALENCE, DISEASE PHENOTYPE AND MAXIMAL THERAPEUTIC STEP IN ULCERATIVE COLITIS PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 2007–2018, DATA FROM THE VESZPREM COUNTY COHORT

Peter L Lakatos  et al.

EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM SURGERY RATES IN CROHN’S DISEASE PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 2007–2018, DATA FROM THE VESZPREM COUNTY COHORT
EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM SURGERY RATES IN CROHN’S DISEASE PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 2007–2018, DATA FROM THE VESZPREM COUNTY COHORT

Peter L Lakatos  et al.

UCEIS IS ASSOCIATED WITH PRO2, PARTIAL MAYO AND SCCAI REMISSION IN UC: PRELIMINARY RESULTS FORM A PROSPECTIVE STUDY
UCEIS IS ASSOCIATED WITH PRO2, PARTIAL MAYO AND SCCAI REMISSION IN UC: PRELIMINARY RESULTS FORM A PROSPECTIVE STUDY

Peter L Lakatos  et al.

EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM COLECTOMY RATES IN ULCERATIVE COLITIS PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 2007–2018, DATA FROM THE VESZPREM COUNTY COHORT
EVOLUTION OF DISEASE PHENOTYPE, TIME TO BIOLOGICAL THERAPY AND MEDIUM-, LONG-TERM COLECTOMY RATES IN ULCERATIVE COLITIS PATIENTS IN WESTERN HUNGARY – A POPULATION-BASED STUDY BETWEEN 2007–2018, DATA FROM THE VESZPREM COUNTY COHORT

Peter L Lakatos  et al.

PATIENT REPORTED OUTCOMES, PARTIAL MAYO SCORE AND SCCAI ARE EQUALLY ACCURATE IN PREDICTING MUCOSAL HEALING IN UC: PRELIMINARY RESULTS FORM A PROSPECTIVE STUDY
PATIENT REPORTED OUTCOMES, PARTIAL MAYO SCORE AND SCCAI ARE EQUALLY ACCURATE IN PREDICTING MUCOSAL HEALING IN UC: PRELIMINARY RESULTS FORM A PROSPECTIVE STUDY

Peter L Lakatos  et al.

CLINICAL EFFICACY, THERAPEUTIC DRUG MONITORING AND NOCEBO EFFECT FOLLOWING NON-MEDICAL BIOSIMILAR SWITCH IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE OBSERVATIONAL STUDY
CLINICAL EFFICACY, THERAPEUTIC DRUG MONITORING AND NOCEBO EFFECT FOLLOWING NON-MEDICAL BIOSIMILAR SWITCH IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A PROSPECTIVE OBSERVATIONAL STUDY

Peter L Lakatos  et al.

TIME TRENDS OF ENVIRONMENTAL AND SOCIOECONOMIC RISK FACTORS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE OVER 40 YEARS OF DIFFERENT THERAPEUTIC ERAS: A POPULATION-BASED COHORT BETWEEN 1977-2020
TIME TRENDS OF ENVIRONMENTAL AND SOCIOECONOMIC RISK FACTORS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE OVER 40 YEARS OF DIFFERENT THERAPEUTIC ERAS: A POPULATION-BASED COHORT BETWEEN 1977-2020

Peter L Lakatos  et al.

Item 1 - 20 / 27
1
2